Orciprenaline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Bradycardia ≤240 mg/day in divided doses. Chronic management of reversible airways obstruction 20 mg 3-4 times/day. IV Bradycardia 250-500 mcg. Inhalation Acute bronchospasm As metered-dose inhaler releasing 750 mcg/inhalation: 1-2 inhalations; repeat if needed. Max: 12 inhalations/24 hr. As 5% soln from a hand nebuliser: 10 inhalations.
Administration
May be taken with or without food.
Contraindications
Cardiac arrhythmias associated with tachycardia.
Special Precautions
CV disease (e.g. arrhythmia, hypertension, CHF), DM, glaucoma, hyperthyroidism, hypokalaemia, seizure disorders. Pregnancy and lactation.
Adverse Reactions
Tachycardia, nervousness, increased serum glucose, increased potassium levels, tremor, palpitation, headache, dizziness, insomnia, nausea, vomiting, bad taste, heartburn, xerostomia, trembling, muscle cramps, weakness, coughing, pharyngitis, increased diaphoresis, paradoxical bronchospasm, hypertension, chest pain, angina, drowsiness, diarrhoea, taste change.
Drug Interactions
Effects may be antagonised by β-blockers e.g. propranolol. Duration of bronchodilation may be increased with inhaled ipratropium. Increased adverse effects with MAOIs, TCAs, sympathomimetics.
ATC Classification
R03AB03 - orciprenaline ; Belongs to the class of adrenergic inhalants, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03CB03 - orciprenaline ; Belongs to the class of adrenergics for systemic use, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on orciprenaline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in